Uniqure NV at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and I'm pleased to welcome uniQure. And with us we have Matt Kapusta, CEO of the company.
Questions & Answers
With that, Matt, thank you for joining us. And to start here, maybe we could talk about the overall strategy for the company here. You've out-licensed the development and commercialization of your lead product or your lead gene therapy product, Phase III EtranaDez in hemophilia B, to CSL Behring. And could you just remind us as to your forward strategy for the overall portfolio, though, focus on neurology and liver disease? And how you're even thinking about BD in that context?
Yes. Sure. Well, thanks for having us, Salveen. Yes, so uniQure's mission still is to be a fully integrated gene therapy
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |